Coronavirus Information for the UC San Diego Community

Our leaders are working closely with federal and state officials to ensure your ongoing safety at the university. Stay up to date with the latest developments. Learn more.

Pharmacomicrobiomics: The holy grail to variability in drug response?

TitlePharmacomicrobiomics: The holy grail to variability in drug response?
Publication TypeJournal Article
Year of Publication2019
AuthorsSharma A., Buschmann M.M, Gilbert J.A
Volume106
Pagination317-328
Date Published2019/08
Type of ArticleReview
ISBN Number0009-9236
Accession NumberWOS:000478601100014
Keywordsbacteria; beta-glucuronidase; cancer drug; efficacy; genistein; gut microbiota modulation; metabolism; pharmacogenomics; Pharmacology & Pharmacy; risk; toxicity
Abstract

The human body, with 3.0 x 10(13) cells and more than 3.8 x 10(13) microorganisms, has nearly a one-to-one ratio of resident microbes to human cells. Initiatives like the Human Microbiome Project, American Gut, and Flemish Gut have identified associations between microbial taxa and human health. The study of interactions between microbiome and pharmaceutical agents, i.e., pharmacomicrobiomics, has revealed an instrumental role of the microbiome in modulating drug response that alters the therapeutic outcomes. In this review, we present our current comprehension of the relationship of the microbiome, host biology, and pharmaceutical agents such as cardiovascular drugs, analgesics, and chemotherapeutic agents to human disease and treatment outcomes. We also discuss the significance of studying diet-gene-drug interactions and further address the key challenges associated with pharmacomicrobiomics. Finally, we examine proposed models employing systems biology for the application of pharmacomicrobiomics and other -omics data, and provide approaches to elucidate microbiome-drug interactions to improve future translation to personalized medicine.

DOI10.1002/cpt.1437
Student Publication: 
No
sharknado